Journal
INFECTION AND IMMUNITY
Volume 69, Issue 6, Pages 4103-4108Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.69.6.4103-4108.2001
Keywords
-
Categories
Ask authors/readers for more resources
Leishmaniasis affects approximately 2 million people each year throughout the world. This high incidence is due in part to the lack of an efficacious vaccine. We present evidence that the recombinant leishmanial antigens LmSTI1 and TSA, which we identified and characterized previously, induce excellent protection in both murine and nonhuman primate (rhesus monkey) models of human cutaneous leishmaniasis. The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available